The role of dupilumab in the management of idiopathic chronic eczematous eruption of aging - 10/10/20
Doi : 10.1016/j.jaad.2020.07.023
Neda Shahriari, MD a, ⁎ 
, Bruce Strober, MD, PhD b, c, Mona Shahriari, MD b, c
, Bruce Strober, MD, PhD b, c, Mona Shahriari, MD b, c a Department of Dermatology, University of Connecticut, Farmington, Connecticut
b Department of Dermatology, Yale University, New Haven, Connecticut
c Central Connecticut Dermatology, Cromwell, Connecticut
∗Correspondence to: Neda Shahriari, MD, 21 South Rd, Farmington, CT 0603221 South RdFarmingtonCT06032
| Funding sources: None. |
|
| Conflicts of interest: Dr Strober receives honoraria as a consultant for AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermavant, Dermira, Janssen, LEO Pharma, Eli Lilly, Meiji Seika Pharma, Novartis, Pfizer, GlaxoSmithKline, UCB Pharma, Sun Pharma, Ortho Dermatologics, Regeneron, and Sanofi-Genzyme; is a speaker for AbbVie, Lilly, Janssen, and Ortho Dermatologics; receives a consulting fee as scientific director for the Corrona Psoriasis Registry; is an investigator for Dermavant, AbbVie, the Corrona Psoriasis Registry, Dermira, Cara, and Novartis; and receives an honorarium as Editor-in-Chief of the Journal of Psoriasis and Psoriatic Arthritis. Dr M. Shahriari receives honoraria as a consultant for AbbVie, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, and Regeneron; is a speaker for AbbVie, Lilly, and Janssen; and is an investigator for AbbVie, the Corrona Psoriasis Registry, Dermira, Cara, Dermavant, and Novartis. Dr N. Shahriari has no conflicts of interest to declare. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the author(s). |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 5
P. 1533-1535 - novembre 2020 Retour au numéro
Article précédent
- Intranasal butorphanol rescue therapy for the treatment of intractable pruritus: A case series from the Johns Hopkins Itch Clinic
- Raveena Khanna, Christina D. Kwon, Sagar P. Patel, Micah Belzberg, Kyle A. Williams, Ramona Khanna, Emily Boozalis, Shawn G. Kwatra
- Systemic rituximab for the treatment of the indolent forms of primary cutaneous B-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry
- Cristina Muniesa, Eva Domingo-Domenech, Rosa Fornons-Servent, Yeray Peñate, M. Teresa Estrach, M. Dolores Ramón, Susana Medina, Ángeles Flórez, Pablo L. Ortiz-Romero, M. Prado Sánchez-Caminero, Ignacio Torres-Navarro, Elvira Acebo, Ignacio Yanguas, Ricardo Fernández-de-Misa, Mar Blanes, Ana Zayas, Miguel A. Descalzo, Ignacio Garcia-Doval, Octavio Servitje
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?